|drug938||Covid19 RT-PCR Wiki||0.71|
|drug3918||lung ultrasound Wiki||0.50|
There are 2 clinical trials
A brief online survey to be completed by clinical therapists.
Description: we are not reporting an overall score on a scale, mostly true false and multiple choiceMeasure: responses to the survey questions Time: measured at the time they take the survey, data collection will continue for up to 1 year.
The aim of the regional online questionnaire is to better understand the pattern of acute infection and the time of recovery of various symptoms.
Description: Percentage of patients manifesting ongoing symptoms after 2 weeks of infection.Measure: Population based data on spectrum and recovery from COVID-19 symptoms Time: two weeks after infection
Description: Spectrum of symptoms at onset and at end of disease.Measure: Population based data on spectrum and recovery from COVID-19 symptoms Time: up to 24 weeks
Description: Identification of symptoms or comorbidities associated with Long-Covid-19.Measure: Predictors of recovery. Time: up to 24 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports